Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Summary

will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study

Timeline

Start

2012-11

Primary completion

2013-10

Completion

2013-10

Outcome

Outcome not reported

Stopped (Enrollment): “Study stopped 10/24/13 secondary to lack of patients/slow enrollment”

Drugs

Indications